Castor, which develops software to run clinical trials, raises $45M Series B, bringing its total raised to $65M
Christine Hall / TechCrunch :
Context & Ripple Effects
Castor's $45M Series B lands in the middle of a crowded funding wave for clinical-trial software. Two weeks earlier, 4G Clinical pulled in $200M from Goldman Sachs; months before that, Reify Health raised a $30M Series B and Hawthorn Effect closed a $20M Series A.
The wave kept building after this round: Medable went on to raise a $304M Series D at a $2.1B valuation, while Koneksa ($45M Series C) and Curebase ($40M Series B for distributed-trial hardware and software) followed into 2022. Castor, at $65M raised in total, is positioned as one of the smaller players racing to digitize how trials are run.
First-order effects
- Castor gains fresh runway to keep pace with far better-capitalized direct rivals — Medable at $2.1B and 4G Clinical at $200M in a single round — in a market where every named competitor has now raised institutional money.
Second-order effects
- Trial sponsors choosing between these vendors get more negotiating leverage as Castor, Curebase, and 4G Clinical bundle competing software offerings, pushing differentiation toward distributed-trial capabilities rather than basic trial management.
Third-order effects
- If the round-size escalation continues, clinical-trial software consolidates around a handful of deeply funded platforms, raising the bar for any new entrant and turning trial-digitization spend toward fewer, larger vendors.
The trend: Venture capital is escalating rapidly into clinical-trial software, moving from tens-of-millions Series Bs to nine-figure mega-rounds in under two years.